オプションチェーンは、Velocity Financialの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Velocity Financialの市場センチメントを評価します。.

Velocity Financial (NYSE:VEL) 株価情報, オプションチェーン

Velocity Financial

Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.

Velocity Financial Inc

Velar - United States Dollar

Velo - United States Dollar

Canadian Overseas Petroleum Ltd

CANADIAN OVRSEA PETE LTD by Canadian Overseas Petroleum Ltd.

<h3>Gainers</h3>
<ul>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 19.4% to $0.88 during Tuesday's pre-market session. The company's market cap stands at $47.0 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares increased by 16.94% to $2.76. The company's market cap stands at $20.2 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock rose 16.11% to $0.28. The market value of their outstanding shares is at $18.3 million. </li>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) shares moved upwards by 14.44% to $3.17. The company's market cap stands at $19.9 million. </li>
<li>Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) stock rose 12.7% to $22.09. The company's market cap stands at $213.7 million. </li>
<li>DatChat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares moved upwards by 9.31% to $3.05. The company's market cap stands at $12.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) stock fell 29.9% to $16.8 during Tuesday's pre-market session. The market value of their outstanding shares is at $991.9 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock decreased by 22.0% to $0.16. The company's market cap stands at $6.0 million. </li>
<li>Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) shares fell 20.54% to $36.5. The company's market cap stands at $4.7 billion. </li>
<li>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares decreased by 16.5% to $146.35. The company's market cap stands at $15.6 billion. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock decreased by 11.5% to $9.01. The company's market cap stands at $150.3 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares declined by 8.93% to $1.53. The market value of their outstanding shares is at $15.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DATS

ENPH

FEIM

FSLR

LDTC

MINM

MOBX

SEDG

SONM

TDTH

XTIA

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Geospace Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEOS#NASDAQ">GEOS</a>) stock rose 13.5% to $7.82 during Tuesday's pre-market session. The market value of their outstanding shares is at $100.1 million. </li>
<li>Houston American Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#AMEX">HUSA</a>) shares increased by 12.35% to $11.91. The market value of their outstanding shares is at $18.6 million. </li>
<li>Indonesia Energy Corp (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INDO#AMEX">INDO</a>) shares increased by 10.02% to $4.39. The company's market cap stands at $59.7 million. </li>
<li>US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) stock increased by 9.62% to $1.88. The company's market cap stands at $63.9 million. </li>
<li>TMD Energy Limited Ordinary Shares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#AMEX">TMDE</a>) stock increased by 8.45% to $2.18. </li>
<li>PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) stock rose 7.59% to $0.71. The market value of their outstanding shares is at $64.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BP Prudhoe Bay Royalty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BPT#NYSE">BPT</a>) shares fell 21.5% to $0.62 during Tuesday's pre-market session. The company's market cap stands at $13.2 million. </li>
<li>Leishen Energy Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NASDAQ">LSE</a>) shares decreased by 13.05% to $5.8. The company's market cap stands at $98.7 million. </li>
<li>Dawson Geophysical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWSN#NASDAQ">DWSN</a>) shares decreased by 10.35% to $2.6. The company's market cap stands at $80.5 million. </li>
<li>Marine Petroleum Tr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARPS#NASDAQ">MARPS</a>) stock decreased by 10.0% to $5.4. The market value of their outstanding shares is at $10.8 million. </li>
<li>Stak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAK#NASDAQ">STAK</a>) shares fell 9.96% to $2.08. The market value of their outstanding shares is at $23.7 million. </li>
<li>Sky Quarry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYQ#NASDAQ">SKYQ</a>) shares declined by 6.48% to $0.82. The market value of their outstanding shares is at $17.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-energy-stocks/" title="www.benzinga.com/money/best-energy-stocks/">www.benzinga.com/money/best-energy-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DWSN

GEOS

HUSA

INDO

MARPS

SKYQ

STAK

TMDE

USEG

12 Energy Stocks Moving In Tuesday's Pre-Market Session

News

INVZ

Innoviz Technologies Signs Statement of Development Work Agreement With A Passenger Automotive Manufacturer To Supply LiDAR Units

Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology&#xAE; platform to accelerate and improve success rates of next-generation drug development
Lisata to lead development efforts to advance GATC's AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026
BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and GATC Health Corp. ("GATC"), a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process.

LSTA

Lisata Therapeutics And GATC Health Announce Strategic Alliance To Accelerate And Improve Success Rate Of Traditional Drug Development Process

Marker Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker's lead Multi-Antigen Recognizing (MAR)-T cell therapy.
MT-601 is currently being investigated in the Phase 1 APOLLO study in patients with lymphoma who relapsed after anti-CD19 chimeric antigen receptor (CAR)-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option (<a href="https://www.globenewswire.com/Tracker?data=Qe_dx69ERis4suOeZax4PPU9fEvzCNEqL2vvY5Iew3aD8J_SYUdrRmb8DvZwp4LgHdlYotbdtNiwQfe-M0f9Uwj1qOh_AEdNCsnj7FgmoB8=">clinicaltrials.gov</a> identifier: NCT05798897). Marker previously reported a favorable safety profile and objective responses in 7 out of 9 study participants (78%), with 4 participants demonstrating complete response (44.4%) as early as 4 weeks after infusion of MT-601 (<a href="https://www.globenewswire.com/Tracker?data=Q4fHSTzZSw8mxNchU0UEEDgRUABe6o1xDvlYJQuVv_5gQIUBkxil9Ng39EzKUU5-0Xjll5asofc4UrRLbJTwf2EB_OUxCEP0hwTDwfvWQvp3YckiyRR1beGsuEI6M3b3JsMGLocdPdskgmcW33MQq-2zriqYrTN6GDccGogtVteRibgkVMU8q05qtkR5XB5ZpS2I1js7dGESyynn7A7zYNHKJfkaMHJZI1KYy6RzKZBZSiZ--sugPEehRTywsikL">Press Release, December 19, 2024</a>).
Under the agreement, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for Marker's APOLLO study. The collaboration between Marker and Cellipont is designed to accelerate clinical supply and lay the foundation for a potential pivotal trial and commercial readiness.

Biotech

General

MRKR

Marker Therapeutics Collaborates With Cellipont Bioservices To Accelerate cGMP Manufacturing Of MT-601 MAR-T Cell Therapy For Lymphoma

Semiconductor specialist Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) easily beat the Monday morning blues with a gargantuan leap in the market. When the dust cleared, AMD stock was up nearly 9% over the prior session. Catapulting sentiment were unconfirmed rumors that the tech giant scored a "<a href="https://www.benzinga.com/trading-ideas/movers/25/06/45955190/amd-stock-is-soaring-monday-whats-going-on">GPU win</a>" with Amazon.com Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) namesake cloud computing platform.
As a result, Piper Sandler analyst Harsh Kumar maintained an Overweight rating and raised AMD's price target to $140 (from $125). Last week, the expert highlighted product launches at the company's "Advancing AI" event. Most notably, the industry was abuzz regarding the<a href="https://www.benzinga.com/markets/tech/25/06/45919591/amd-challenges-nvidias-ai-dominance-with-new-helios-server-as-openai-ceo-sam-altman-confirms-chatgpt-will-use-lisa-su-led-tech-giants-latest-chips-future-of-ai-is-not-going-to-be-built-b"> Helios rack</a>, a system comprising 72 advanced graphics processors for the purpose of powering data centers.
Still, with so much enthusiasm baked into AMD stock, investors may wonder if there are additional supporting narratives. Primarily, the bulls will likely point to the continued expansion of machine intelligence. Earlier this month, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) generated headlines on news that it is considering a<a href="https://www.benzinga.com/m-a/25/06/45839465/zuckerbergs-ai-push-expands-meta-weighs-10b-stake-in-scale-ai"> multi-billion-dollar investment</a> into Scale AI, which helps companies train AI models.
Per a Bloomberg report, the investment could top $10 billion in value, reflecting sustained growth in the digital automation realm. Subsequently, interest in AI may help boost GPU sales.
Another positive storyline again comes from Amazon. Just recently, the e-commerce juggernaut announced plans to invest the equivalent of approximately $13.02 billion through 2029 to<a href="https://www.benzinga.com/markets/equities/25/06/45943758/amazon-commits-13-billion-to-expand-australias-ai-data-center-infrastructure"> expand its data center infrastructure</a> across Australia. Again, such fundamental factors lend credence to the belief that Advanced Micro can benefit from increased demand for its data center products.
Still, every investment carries risks, and AMD stock is no exception. While Advanced Micro has made significant progress in the fabless semiconductor realm, it's an arena dominated by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). It's also not particularly close. At the time of writing, Nvidia commands a market capitalization of $3.53 trillion. In contrast, AMD is looking at just under $205 billion.
Another point to consider is that the personal computer market is<a href="https://www.pcworld.com/article/2581409/the-pc-market-grew-only-1-3-in-2024.html"> mature</a>. In particular, consumer PC sales have slowed since the COVID-19 crisis, thus hurting Advanced Micro's traditional CPU and GPU business. It also doesn't help that the PC market only grew about 1.3% last year, reflecting wider challenges.
The Direxion ETFs: With competing narratives clashing for a popular enterprise, those interested in trading AMD stock may consider Direxion's leveraged and inverse exchange-traded funds. For the bulls, the Direxion Daily AMD Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMUU#NASDAQ">AMUU</a>) seeks the daily investment results of 200% of the performance of AMD stock. On the other end, the Direxion Daily AMD Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMDD#NASDAQ">AMDD</a>) seeks 100% of the inverse performance of the namesake equity.
Primarily, the relevance of these Direxion ETFs focuses on providing a convenient mechanism for speculation. Typically, those interested in leveraged opportunities or short positions must engage the options market. However, these derivative instruments can be incredibly complex. Direxion ETFs, on the other hand, can be bought and sold, much like any other publicly traded security, thus mitigating the learning curve.
Nevertheless, prospective participants should be cognizant of the risks. First, inverse and leveraged ETFs tend to be much more volatile than standard funds tracking benchmark indices. Also, the tracking of a single entity makes it subject to wild swings. Second, Direxion ETFs are designed for exposure lasting no longer than one day. Holding beyond the recommended period may expose traders to value decay due to the daily compounding effect.
The AMUU ETF: Making its public market debut in February of this year, the AMUU ETF is off to a decent start, gaining almost 8%.
<ul class="wp-block-list">
<li>Previously, AMUU was bouncing off the 20-day exponential moving average (EMA), which represented support. With Monday's big pop, the bull fund is firmly above this near-term gauge.</li>
<li>What's encouraging about Monday's jump of 17.5% was that it was also accompanied by a massive spike in volume.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1001" height="635" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png" alt="" class="wp-image-952124" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-300x190.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-768x487.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></figure>
The AMDD ETF: Also making its debut in February, the AMDD ETF isn't quite as fortunate, losing more than 22% of value.
<ul class="wp-block-list">
<li>Contrary to what was witnessed in the bullish counterpart, the AMDD ETF's 20-day EMA has acted as resistance.</li>
<li>Huge distributive volume accompanied Monday's selloff in AMDD. Moving forward, it likely must regain control of $20 to instill confidence.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1001" height="635" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png" alt="" class="wp-image-952123" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-300x190.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-768x487.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></figure>
Featured image by <a href="https://pixabay.com/users/artificialog-1886751/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5250769">ArtificialOG</a> from <a href="https://pixabay.com/photos/amd-ryzen-cpu-processor-pc-chip-5250769/">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

AMDD

AMUU

AMZN

NVDA

Advanced Micro Devices' Demand Spike Draws Intrigue For Direxion's AMD-Focused Bull And Bear Funds

Weight Loss drug maker Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has agreed to acquire Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), a Boston-based clinical-stage company developing genetic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45968442/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovasc" rel="noreferrer noopener">medicines for cardiovascular disease</a>.
Verve&#8217;s lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to <a href="https://www.benzinga.com/general/health-care">cholesterol levels and cardiovascular health</a>.
The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH), a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease (CAD).
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499" target="_blank" rel="noreferrer noopener">Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499</a>
VERVE-102 is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration.
In April, Verve Therapeutics released initial data from the Heart-2 Phase <a target="_blank" href="https://www.benzinga.com/25/04/44793762/verve-therapeutics-touts-positive-data-from-gene-editing-medicine-to-lower-cholesterol-after-single-dose" rel="noreferrer noopener">1b trial of VERVE-102</a>.
VERVE-102 was well-tolerated among 14 participants across three dose levels. No treatment-related serious adverse events (SAEs) and no clinically significant laboratory abnormalities were observed.
A single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 protein (regulates cholesterol metabolism) levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.
Lilly has offered to purchase Verve for $10.50 per share in cash, an aggregate of approximately $1.0 billion, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash, an aggregate of up to approximately $1.3 billion).
CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 trial on or before the tenth anniversary of closing or termination of the CVR.
The transaction is expected to close in the&nbsp;third quarter of 2025.
The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve&#8217;s common stock ended on June 16, 2025, the last trading day before the deal announcement.
Price Action: LLY stock is down 0.89% at $800.42, and VERV stock is up 75.9% at $11.03 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45263363/crispr-therapeutics-data-provides-promising-balance-rfk-jr-appointee" target="_blank" rel="noreferrer noopener">CRISPR Therapeutics&#8217; Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst</a></li>
</ul>
Image via Shutterstock

Large Cap

Health Care

VERV

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition

Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines
IMUNON Seeks Strategic Partner for PlaCCine&#xAE; to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital
LAWRENCEVILLE, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LMqjJaivBIT7adjV5w8R1FSDUnhwOcWpPQxmLP3q_lKYT32er9nqocniZ8hCTgyMJGnmKBAJI4FRdl9iVGalCnz02sYZhe0D4LJzGTPoZf7IHuEHv6FHBXSoBWBzVF2UFFJjuj13zRovCbTKGKjqSJo5mLmAiQSMwqA8g3Gro4pm_eyKowG3OZpJyAA-a0wMkA80ESYs8ZP0lUAInY92ax98OtEuvHL1wxgEmZcX0HHCdpXyUzuPtG_DiZwociRCY7vQW5mmg6mxypkLQoBUeJP9UErLXLohZmSO13dGnZAQd27LGHruTYQE3tmUbqe3MX4SR4J0UJpM1TGcYBBUKd505NgmItIRpeYUin9pZZ0QB6YHWgN8_NuTg4djwRrv">IMUNON, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced that an abstract highlighting Phase 1 proof-of-concept clinical trial results of IMNN-101, an investigational DNA plasmid vaccine based on the Company's proprietary PlaCCine&#xAE; technology platform, was accepted for oral presentation at the 10th International Conference on Vaccines Research &amp; Development. The meeting is being held November 5-7, 2025, in Boston, MA.
In the Phase 1 trial, designed to demonstrate the potential of IMUNON's technology as a viable alternative to current vaccines including approved messenger RNA (mRNA) vaccines, IMNN-101 was administered as a single dose vaccine without a booster dose in study participants who were previously vaccinated against the Omicron XBB1.5 variant. Study participants had high baseline immune characteristics, presumably from prior infection and/or multiple previous vaccinations against COVID-19, and ongoing infection. Modest increases in T-cell responses were seen in trial participants who received multiple immunizations before the study.
In May 2025, IMUNON announced positive six-month data from the Phase 1 trial demonstrating better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen variant. Results also showed IMNN-101 induced up to a 3-fold median increase in the serum neutralizing antibody (NAb) titers from baseline at six months, with initial evidence of a stronger immune response in the two higher dose cohorts (2.0 mg and 1.0 mg) compared to the lower dose cohort (0.5 mg). IMNN-101 was shown to be safe and well tolerated, with no serious adverse effects reported.

IMNN

IMUNON Showcases PlaCCine Vaccine's Six-Month Durability, Stability, And Manufacturing Edge Over mRNA; Seeks Strategic Partner For Advancement

CPI Aerostructures, Inc. ("CPI Aero&#xAE;" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVU#NYSE">CVU</a>) announced today that it has signed another Long-Term Agreement ("LTA") with MST Manufacturing ("MST") during the international air show in Paris, France, for the supply of components in support of its aerostructures production. This LTA will cover CPI Aero's requirements from MST through the end of calendar year 2028.

CPI Aerostructures Signs Another LTA With MST Manufacturing During International Air Show In Paris, For Supply Of Components In Support Of Aerostructures Production

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jabil.com%2F%3Futm_medium%3Dpr%26utm_source%3Dpress-release%26utm_campaign%3Dus-manufacturing&amp;esheet=54276766&amp;newsitemid=20250617413912&amp;lan=en-US&amp;anchor=Jabil+Inc.&amp;index=1&amp;md5=f555c35c28a12cea989f7478924a4e2f">Jabil Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), a global leader in engineering, supply chain, and manufacturing solutions, today announced it intends to invest approximately $500 million over the next several years to expand its footprint in the Southeast United States to support <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jabil.com%2Findustries%2Fcloud-data-centers.html%3Futm_medium%3Dpr%26utm_source%3Dpress-release%26utm_campaign%3Dus-manufacturing&amp;esheet=54276766&amp;newsitemid=20250617413912&amp;lan=en-US&amp;anchor=cloud&amp;index=2&amp;md5=a7bae53243efa2fdc9f2f334e6513eff">cloud</a> and AI data center infrastructure customers. This significant commitment will enable new large-scale manufacturing capabilities, capital investments, and workforce development.
Jabil is in the final stages of site selection and expects it to be operational by mid-calendar year 2026.

Jabil Intends To Invest ~$500M Over Next Several Years To Expand Footprint In Southeast United States To Support Cloud And AI Data Center Infrastructure Customers

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Financing

Markets

DDC Enterprise Enters Three Securities Purchase Agreements For Total Gross Proceeds Up To $528M; Proceeds Will Be Used To Expand Bitcoin Treasury

WIIM

BKYI

BIO-key shares are trading higher after the company received over $600K in follow-on orders from an international defense ministry.

Subscription sales expected to reach $700K–$800K in Q2 2025, up from $389K in Q1
ATLANTA, GA, June 17, 2025 (GLOBE NEWSWIRE) -- Vaunt, the spontaneous private aviation platform operated by Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>), today announced projected Q2 2025 subscription sales between $700,000 and $800,000—potentially doubling the first quarter and continuing a rapid growth trajectory that began in late 2024.
This performance builds on subscription sales of $389,000 in Q1 2025. The continued acceleration underscores growing demand for Vaunt's one-of-a-kind private flight experiences and its ability to convert engagement into recurring revenue.

SOAR

Volato Group's Vaunt Projects Q2 Subscription Sales Between $700K And $800K, Up From $389K In Q1

AZTR

Azitra Reports Safety Data From Phase 1b Trial Of ATR12-351 Netherton Syndrome; Says ATR12-351 Has Been 'generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site'

Offerings

ADIL

Adial Pharmaceuticals Prices 11M. Share Reasonable Best Efforts Offering At Combined Offering Price Of $0.3251 Per hare And Accompanying Warrants

ECDA

ECD Automotive Design Unveils One-Of-One Jaguar E-Type GTO Under Bridgewater Commission As Ultimate Bespoke Grand Tourer

Shares of Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) jumped by nearly 9%, moving above the key support level after seven months on Monday. This was driven by a possible partnership with Amazon.com Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Services (AWS).
What Happened: On Monday, AMD gained 8.81% to jump above its 200-day simple daily moving average of $116.98 apiece.
This was fueled by a positive <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45955190/amd-stock-is-soaring-monday-whats-going-on">update from Piper Sandler</a> and unconfirmed rumors that the company scored a "GPU win" with Amazon Web Services.
The stock moved higher than its 200-day SMA for the first time in over seven months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24AMD&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMD</a> just closed above its 200-day SMA for the first time in over seven months. Comeback season is in full swing. &#x1f501; <a href="https://t.co/7W9gKxCtoR">pic.twitter.com/7W9gKxCtoR</a>
&mdash; TrendSpider (@TrendSpider) <a href="https://twitter.com/TrendSpider/status/1934747821829444045?ref_src=twsrc%5Etfw">June 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The stock was still below its 50-day SMA with a relative strength index in the neutral zone at 57.68.
Meanwhile, the current MACD reading for AMD shows a bullish signal. The MACD line of 0-2.43 is above the signal line of -6.82, and the positive histogram value of 4.39 confirms this bullish cross.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022124/AMD-Tech-CHart-1024x576.png" alt="" class="wp-image-951644" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022124/AMD-Tech-CHart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022124/AMD-Tech-CHart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022124/AMD-Tech-CHart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022124/AMD-Tech-CHart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022124/AMD-Tech-CHart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
While the technical indicators point towards a buying opportunity, about <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">37 analysts tracked by Benzinga</a> have a consensus &#8216;buy&#8217; rating and average price target of 140.94 apiece. The targets range from $95 to $200. Recent ratings from Piper Sandler, Stifel, and Roth Capital imply a 12.48% upside for the stock.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AMD/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="387" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17035244/AMD-ANR-1024x387.png" alt="" class="wp-image-951794" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17035244/AMD-ANR-1024x387.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17035244/AMD-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17035244/AMD-ANR-768x290.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17035244/AMD-ANR.png 1282w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/markets/commodities/25/06/45948096/exxon-mobil-chevron-occidental-petroleum-in-focus-as-expert-says-us-economy-is-far-less-sensitive-to-an-oil-shock-amid-israel-iran-conflict">Exxon Mobil, Chevron, Occidental Petroleum In Focus As Expert Says &#8216;US Economy Is Far Less Sensitive To An Oil Shock&#8217; Amid Israel-Iran Conflict</a>
Why It Matters: On June 16, Piper Sandler&#8217;s Harsh Kumar reiterated an &#8216;overweight&#8217; rating on AMD, raising the price target to $140.
Kumar is optimistic about AMD&#8217;s GPU business, expecting a fourth quarter rebound after China-related charges. He forecasts third-quarter 2025 AI business growth to offset these charges.
Notably, Kumar highlighted AMD&#8217;s strong, multi-level relationship with Amazon, a key customer for both CPUs and GPUs. This <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45955190/amd-stock-is-soaring-monday-whats-going-on">unconfirmed GPU deal</a> with AWS likely fueled Monday&#8217;s AMD stock surge. Amazon&#8217;s prior $84.4 million stake in AMD, from the ZT Group acquisition, further underscores this relationship.
According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, AMD&#8217;s forward price-to-earnings ratio stood at 33.898 times the 2026 earnings, whereas the industry average was at 37.030 times. This meant that the stock was trading at a forward price of 0.92 times in comparison with its peers. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>Forward P/E</td>
<td>Industry Average</td>
</tr>
<tr>
<td>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>33.898</td>
<td>37.03</td>
</tr>
<tr>
<td>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>33.784</td>
<td>37.03</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>38.462</td>
<td>37.03</td>
</tr>
<tr>
<td>Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)</td>
<td>22.523</td>
<td>&#8211;</td>
</tr>
<tr>
<td>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</td>
<td>36.232</td>
<td>37.03</td>
</tr>
</tbody>
</table>
</figure>
The shares have risen 4.77% on a year-to-date basis, and dropped by -20.21% over a year. 
Benzinga Edge Stock Rankings shows that AMD had a stronger price trend over the short and medium term but a weaker price trend over the long term. Its momentum ranking was weak; however, its value ranking was poor at the 16.13th percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="153" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022006/AMD-Edge-1024x153.png" alt="" class="wp-image-951643" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022006/AMD-Edge-1024x153.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022006/AMD-Edge-300x45.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022006/AMD-Edge-768x115.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17022006/AMD-Edge.png 1044w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, advanced on Monday. The SPY was up 0.95% at $602.68, while the QQQ advanced 1.39% to $534.29, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
The futures of the Dow Jones, S&amp;P 500, and Nasdaq 100 indices were trading lower on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45950097/war-shocks-could-drag-sp-500-down-5-but-market-typically-roars-back-heres-what-data-from-25-wars-70-years-shows">War Shocks Could Drag S&amp;P 500 Down 5% — But Market Typically Roars Back: Here&#8217;s What Data From 25 Wars, 70 Years Shows </a></li>
</ul>
Photo courtesy: JHVEPhoto / Shutterstock.com

Equities

AVGO

AMD Stocks Rips 9% Amid Possible AWS Partnership: Should You Buy or Sell? Key Metrics Reveal the Answer

<a href="https://www.globenewswire.com/Tracker?data=10skfib_ltp_ad7vReOEaSfcRcXZ8f0blSR41QSAq-fjaClDdw6TOf2uPe8tLRfZOVjdr2X1FoMg6q25mA6AhHwfbEl9OuLJsFE1R9PGtzo=">BIO-key&#xAE; International, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring <a href="https://www.globenewswire.com/Tracker?data=_tgeAe6LGGjzTzP8JPEhMqL__gSWJxUb5AAMpYCDdCwwAfkNHEJP6Ze3SuH8Ai9r61SXYy6BDYTYGjazIaDARJAgRdWL41dB1axX_TCVx31tObx9jaOjXcvybmBa5YuOU9sZM0-nxRYO6feX2AYCJQr7c90g3ODigBMgXIWqFdU=">Identity-Bound Biometrics</a> (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that the cyber-defense unit of one of the world's most renowned defense ministries has placed over $600K in new orders for BIO-key's biometric user authentication solution. The orders are for additional biometric hardware and authentication software to be shipped in the current quarter.
The defense ministry has deployed BIO-key's biometric authentication solution into new programs delivering convenient and positive authentication access to digital services for over 47,000 users utilizing over 40,000 BIO-key fingerprint scanners. BIO-key expects additional awards in future periods as the defense ministry expands the use of its solution.

BIO-key Secures $600K Order From International Defense Ministry For Biometric User Authentication Solution

There&#8217;s a good chance your retirement strategy is quietly sabotaging your future. It&#8217;s not about making one catastrophic mistake; it&#8217;s about the small, common missteps that compound over time, draining your nest egg without you even noticing.&nbsp;
For many, by the time the damage becomes clear, it&#8217;s already too late.
Here are seven of the most destructive moves that can derail your retirement goals.
<h2 class="wp-block-heading">1. Thinking Your 401(k) Is a Retirement Plan</h2>
Most people with a 401(k) think they&#8217;re covered. They&#8217;re not. A 401(k) is a tool, not a plan. It might offer a match, but it also locks up your money until you're over 60, comes with limited investment choices, and often hides high fees behind default options.
Even more concerning, average 401(k) balances for people in their 60s sit under $130,000. That's nowhere near enough to fund two or three decades of life after work. And by the time most people realize it, they're already on the way out of the workforce.
<h2 class="wp-block-heading">2. Letting Fear or Headlines Dictate Your Moves</h2>
Markets go through chaos. Elections bring uncertainty. The news cycle is always looking for the next crisis.
Letting fear decide when to invest, or when to pull out, is not a strategy. It's just reacting. And the people who do that consistently are the ones who miss the strongest rebounds.
They sell low, buy back in late and repeat the cycle. Then they wonder why their portfolio never seems to grow the way it should.
Check out: A new investment strategy gaining popularity among institutional investors can provide positive returns even in a down market. <a href="https://www.benzinga.com/money/wall-street-quietly-moved-into-a-34-trillion-market-now-accredited-investors-can-too">Individuals are now using this same strategy to protect their retirement portfolios and grow their wealth</a>.&nbsp;
<h2 class="wp-block-heading">3. Underestimating How Much You&#8217;ll Actually Need</h2>
There's a dangerous assumption that retirement comes with lower expenses. Sometimes it does. But not always.
Medical costs tend to increase, travel becomes more frequent, adult kids might still need help and homes still need work. Roofs leak, appliances break, and nothing gets cheaper over time.
If you're only planning to replace your current paycheck, you&#8217;re likely underestimating the true cost of retirement. Add in inflation, and what feels like a solid nest egg today might fall short far sooner than expected.
<h2 class="wp-block-heading">4. Ignoring the Silent Killer: Fees</h2>
Fees don't feel urgent, but they're relentless. A seemingly small 1.5% annual fee can take a huge bite out of your retirement savings over time, often hundreds of thousands of dollars lost to advisors or fund managers who may not even outperform the market.
Consider this: A 1.5% annual fee on a $250,000 portfolio costs you $3,750 this year. Over 20 years, with compounding, that &#8216;small&#8217; fee could erase over $150,000 from your final nest egg.
Many people have no idea what they're actually paying. Default mutual funds in 401(k)s often come with management layers, administrative charges, and hidden fund-level fees. It adds up, year after year.
<h2 class="wp-block-heading">5. Relying Too Heavily on Wall Street and Ignoring What the Wealthy Are Actually Doing</h2>
Most portfolios are built entirely on public stocks and bonds. And most of them look pretty much the same. That simplicity can be comforting, but it also leaves you exposed.
The wealthiest investors don't leave everything in the hands of Wall Street. They put capital into assets that don't move with the market: private real estate, private credit, farmland, venture capital and other assets that don't follow the same market cycles as stocks and bonds.
These aren't just vanity investments. They offer cash flow, long-term appreciation, and insulation from the emotional swings of public markets. If your entire portfolio is tied to the same indexes and headlines, you&#8217;re missing a layer of protection and opportunity that more sophisticated investors rely on.
Don't miss: One of the fastest-growing private real estate strategies isn't buying or renting homes,&nbsp; it's investing in home equity. <a href="https://www.benzinga.com/money/wall-street-quietly-moved-into-a-34-trillion-market-now-accredited-investors-can-too">See how the wealthiest investors are tapping into this market.</a>
<h2 class="wp-block-heading">6. Treating Your Retirement Account Like a Backup Plan Instead of a Priority</h2>
Too many people only contribute to retirement when they "have extra." Which usually means they don't contribute much at all.
The problem is that the longer you wait, the more expensive retirement becomes. Skip the early years and you don't just miss out on what you could've saved, you lose the decades of growth those early contributions would have generated.
The people who retire with confidence aren't usually the ones who made big bets or had perfect timing. They're the ones who treated retirement like a bill that had to be paid every month, no matter what.
<h2 class="wp-block-heading">7. Ignoring the $34 Trillion Opportunity Under Your Feet</h2>
For millions of Americans, their single largest asset is their home, containing trillions of dollars in collective equity. Yet, for most, this wealth is completely illiquid and not part of their investment strategy.
While the ultra-wealthy have long used real estate as a core holding, there's a new trend of Wall Street: finding ways to invest in the appreciation of residential real estate without the burden of being a landlord.&nbsp;
This asset class, which doesn&#8217;t move with the stock market, is increasingly being used by institutional investors to diversify and add a layer of protection against market volatility.
From real estate investment trusts (REITs) focused on single-family homes to newer investment vehicles that buy into home equity agreements, investors are finding ways to unlock the largest source of wealth for Americans. Exploring how to add real estate exposure beyond your primary residence can be a powerful engine for a more resilient retirement portfolio.
Read next: Wall Street has been quietly buying up equity in owner-occupied homes, and the strategy is kind of genius. <a href="https://www.benzinga.com/money/wall-street-quietly-moved-into-a-34-trillion-market-now-accredited-investors-can-too">Here&#8217;s how one company is using it to produce 15%+ annual returns for its investors.</a>
Image: Shutterstock

Real Estate

7 Moves That Will Destroy Your Retirement Account

U.S. stock futures were lower this morning, with the Dow futures falling more than 200 points on Tuesday.
Shares of Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/RDW">announced a $200 million common stock offering.</a>
Redwire shares dipped 10.1% to $18.48 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares tumbled 27.4% to $7.00 in pre-market trading. Jefferies, last week, downgraded the stock from Hold to Underperform and lowered its price target from $6 to $5.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) dipped 21.5% to $18.79 in pre-market trading. Barclays analyst Christine Cho, last week, maintained SolarEdge Technologies with an Underweight and raised the price target from $11 to $12.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) declined 16.7% to $38.28 in pre-market trading.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) declined 10.1% to $157.00 in pre-market trading. Jefferies analyst Julien Dumoulin-Smith, last week, upgraded First Solar from Hold to Buy and raised the price target from $157 to $192.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) fell 9.2% to $7.23 in pre-market trading.</li>
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) declined 8.6% to $12.80 in pre-market trading after dipping 13% on Monday.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) dipped 7.1% to $93.68 in pre-market trading as the company announced a proposed primary offering of ordinary shares.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) dropped 6.7% to $56.67 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45966402/jabil-lennar-and-3-stocks-to-watch-heading-into-tuesday">Jabil, Lennar And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ARRY

LZMH

MMYT

Redwire, MakeMyTrip And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Press Releases

Velocity Financial, Inc. Announces Date of Second Quarter 2024 Financial Results Webcast and Conference Call

Velocity Financial, Inc. Reports Second Quarter 2024 Results

Velocity Financial, Inc. Announces Date of Third Quarter 2024 Financial Results Webcast and Conference Call

Velocity Financial, Inc. Reports Third Quarter 2024 Results

Velocity Financial, Inc. Announces Date of Fourth Quarter and Full-Year 2024 Financial Results Webcast and Conference Call

Velocity Financial, Inc. Reports Fourth Quarter and Full Year 2024 Results

Velocity Financial, Inc. Announces Date of First Quarter 2025 Financial Results Webcast and Conference Call

Velocity Financial, Inc. Reports First Quarter 2025 Results

Enact Holdings

Federal Agricultural Mortgage Corporation Common Stock

Federal Agricultural

Better Home & Finance Holding Company - Class A Common Stock

Better Home & Finance

Mr. Cooper Gr

Essent Group

Finance of America Companies Inc. Class A Common Stock

Finance of America

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Comments

Velocity Financial

Velocity Financial (VEL) オプション

Velocity Financial (NYSE:VEL) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル